IOL Chemicals and Pharmaceuticals growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+11.5%+1.5%
EBITDA+33.0%+6.0%
Net Income+36.2%−0.4%
EPS (adj.)+36.2%−0.4%
Total Assets+8.6%+8.6%
Total Equity+6.6%+6.1%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

IOLCP₹180.62

IOL Chemicals and Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersMOREPENLABFDCINNOVACAPORCHPHARMASENORESSANOFIGUJTHEMRPGLIFEMcap ₹5,302 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+11.5+1.5
EBITDA+33.0+6.0
Net Income+36.2-0.4
EPS (adj.)+36.2-0.4
Total Assets+8.6+8.6
Total Equity+6.6+6.1
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.